OncRef

Clinical Trial: NCT04484142

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Daiichi Sankyo
Information Provided By:Daiichi Sankyo
Last Update Posted:2026-03-24

Study Overview

Brief Summary

This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.

Official Title

Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations and Progressed On or After Applicable Targeted Therapy and Platinum Based Chemotherapy (TROPION-Lung05)

Conditions

Non-small Cell Lung Cancer

Intervention / Treatment

  • Drug: DS-1062a

Other Study ID Numbers

  • DS1062-A-U202
  • 2020-002774-27
  • 2024-511449-21-00

Start Date (Actual)

2021-03-30

Primary Completion Date (Actual)

2023-03-10

Study Completion Date (Actual)

2026-02-04

Enrollment (Actual)

137

Study Type

Interventional

Phase

Phase 2